147 related articles for article (PubMed ID: 1479751)
1. [Lysis of autologous tumor cells by peripheral blood lymphocytes treated with IFN-alpha in patients with renal cell carcinoma].
Kubota S
Nihon Hinyokika Gakkai Zasshi; 1992 Nov; 83(11):1781-8. PubMed ID: 1479751
[TBL] [Abstract][Full Text] [Related]
2. Enhanced susceptibility of c-myc antisense oligonucleotide-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes.
Mizutani Y; Bonavida B; Fukumoto M; Yoshida O
J Immunother Emphasis Tumor Immunol; 1995 Feb; 17(2):78-87. PubMed ID: 7647959
[TBL] [Abstract][Full Text] [Related]
3. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
Hermann GG
APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
[No Abstract] [Full Text] [Related]
4. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment.
Schendel DJ; Gansbacher B
Cancer Res; 1993 Sep; 53(17):4020-5. PubMed ID: 8358731
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
6. Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.
Belldegrun A; Pierce W; Kaboo R; Tso CL; Shau H; Turcillo P; Moldawer N; Golub S; deKernion J; Figlin R
J Urol; 1993 Nov; 150(5 Pt 1):1384-90. PubMed ID: 8411405
[TBL] [Abstract][Full Text] [Related]
7. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
[TBL] [Abstract][Full Text] [Related]
8. Lysis of autologous tumor cells by peripheral blood lymphocytes treated with interleukin 2 in patients with renal cell carcinoma.
Nakano E; Tada Y; Ichikawa Y; Fujioka H; Matsuda M; Takaha M; Sonoda T
J Urol; 1987 Apr; 137(4):641-8. PubMed ID: 3494137
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha-induced protection of renal cell cancer cell line from lysis by natural killer cells and increase of susceptibility by treatment with 5-fluorouracil.
Imai T; Katagiri A; Saito K; Tomita Y
Cancer Lett; 1995 Aug; 94(2):191-7. PubMed ID: 7634247
[TBL] [Abstract][Full Text] [Related]
10. Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells.
Tomita Y; Watanabe H; Kobayashi H; Nishiyama T; Tsuji S; Fujiwara M; Sato S
Cancer Immunol Immunother; 1992; 35(6):381-7. PubMed ID: 1356627
[TBL] [Abstract][Full Text] [Related]
11. Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity.
Nishimura T; Terashima Y; Hattori T; Satoh M; Kondo Y; Kimura G; Yoshida K; Akimoto M
Urol Int; 1991; 47 Suppl 1():83-5. PubMed ID: 1949387
[TBL] [Abstract][Full Text] [Related]
12. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
[TBL] [Abstract][Full Text] [Related]
13. [Cell therapy in renal cell carcinoma].
Ravaud A
Bull Cancer; 2003; 90(8-9):711-21. PubMed ID: 14609761
[TBL] [Abstract][Full Text] [Related]
14. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma.
Donskov F; Bennedsgaard KM; Hokland M; Marcussen N; Fisker R; Madsen HH; Fode K; von der Maase H
Cancer Immunol Immunother; 2004 Aug; 53(8):729-39. PubMed ID: 15088127
[TBL] [Abstract][Full Text] [Related]
15. Use of cryopreserved lymphocytes for assessment of the immunological effects of interferon therapy in renal cell carcinoma patients.
Sobota V; Bubeník J; Indrová M; Vlk V; Jakoubková J
J Immunol Methods; 1997 Apr; 203(1):1-10. PubMed ID: 9134025
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
Belldegrun A; Muul LM; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
18. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
[TBL] [Abstract][Full Text] [Related]
19. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
Gratama JW; Schmitz PI; Goey SH; Lamers CH; Stoter G; Bolhuis RL
Int J Cancer; 1996 Jan; 65(2):152-60. PubMed ID: 8567110
[TBL] [Abstract][Full Text] [Related]
20. [Immunological effect of recombinant interferon-gamma in renal cell carcinoma].
Kawata N; Ono M; Endo M; Ichinose T; Hamada T; Hirano D; Fuse T; Takimoto Y
Hinyokika Kiyo; 1993 Jun; 39(6):511-5. PubMed ID: 8337976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]